L19IL2
Sponsors
Philogen S.p.A.
Conditions
Advanced Solid TumoursFAPLocally Advanced Basal Cell CarcinomaMelanoma Stage IIIMelanoma Stage IVMetastatic Colorectal Carcinoma (mCRC)Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Metastatic
Phase 1
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
CompletedNCT01058538
Start: 2005-11-30End: 2009-11-30Updated: 2014-02-25
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
RecruitingNCT06640413
Start: 2025-10-31End: 2028-12-31Target: 56Updated: 2026-01-14
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Not yet recruitingNCT07566897
Start: 2026-05-01End: 2030-05-01Target: 96Updated: 2026-05-05
Phase 2
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RecruitingNCT06284590
Start: 2024-07-12End: 2028-07-31Target: 162Updated: 2024-10-26
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Not yet recruitingNCT07227350
Start: 2026-02-01End: 2031-02-01Target: 180Updated: 2026-03-10